Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss Nycomed has acquired a majority stake in Guangdong Techpool Bio-Pharma for €210 million to expand its Chinese operations.

You may also be interested in...

Nycomed To Beef Up Sales In China Through Buyout; Bets On India For Global API Supplies

MUMBAI - Having established itself firmly among the top 10 pharma companies in Russia, Zurich-headquartered Nycomed now plans to dig deeper into the fast-growing Chinese market through the acquisition of a sales and distribution team

Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen

Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.

Denmark's IO Vaccine Biotech Attracts Investor Interest

Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts